Navigation Links
Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest

The development of new and innovative pharmaceuticals is being stifled by a U.S. law and successful patent challenges that embolden generic competition, according to an article published in this week's issue of the journal Science.

Matthew Higgins and Stuart Graham, assistant professors in the College of Management at the Georgia Institute of Technology, argue in their article that the recent surge in Paragraph IV patent challenges -- a provision of the Hatch-Waxman Act of 1984 -- is decreasing the incentives for pharmaceutical innovation and contributing to productivity and revenue declines in the pharmaceutical industry.

"With the current healthcare debate, consumers and policy-makers need to understand that while we are getting cheap drugs now, it may be at the cost of novel future innovations and long-term access to new treatments because in our current system, industry revenues support continued research and development, and patents support revenues," explained Higgins, the Imlay assistant professor of strategic management at Georgia Tech.

While Congress passed the Hatch-Waxman Act to ensure timely, affordable access to innovative drugs, 25 years later its balance between pharmaceutical innovation and access is tipping away from the incentives needed to support innovation, the researchers said.

A contributor to this shift is the recent surge in Paragraph IV challenges, which allow manufacturers of generic drugs to challenge a brand company's patents by claiming that either the patent is invalid or the generic drug does not infringe the patent. If the generic company wins the challenge, the brand company loses its remaining market exclusivity for that product.

Federal Trade Commission statistics show that generic firms won 42 percent of the Paragraph IV challenges filed from 1992 to 2000. Since 2001, pharmaceutical companies have filed 749 lawsuits responding to Paragraph IV challenges on 243 unique brand-name products. These suits nearly tripled from 2002-2003 and doubled from 2006-2007.

"A Paragraph IV lawsuit will likely cost a generic manufacturer $5 to $10 million, compared to at least $800 million required for a brand company to develop a drug and bring it to market," said Graham, who is also a licensed attorney. "And the reward for being the first successful Paragraph IV challenger is substantial -- 180 days during which no other generic-producing company may enter the market and an average potential payoff during those 180 days alone of $60 million. The law is creating incentives to bring challenges on more and different types of drugs."

As the number of patent challenges has increased, the number of new compounds approved annually by the U.S. Food and Drug Administration (FDA) has fallen from an average of 35 in 1996-2001 to 20 in 2002-2007. Without policy intervention, the effective life of key patents will continue to decline, which will further compress the payback period during which brand-name firms can recoup research and development investments, according to the researchers.

"Lawmakers should consider increasing the length of time brand-name drugs are on the market before generic drugs can enter, because the current five-year period is typically insufficient to recoup research and development costs," added Higgins.

Graham and Higgins suggest that exclusivity be extended for first-in-class and high-risk, high-necessity drugs, such as a preventive medicine for Alzheimer's disease or osteoarthritis. In addition, they propose that policy-makers use incentives to encourage private investments in research to complement public research or offer increased exclusivity to curative and preventive drugs. Auctions could allow companies to bid on specific research projects in return for extended data or market exclusivity.

A 2007 report from The National Academies recommended that the United States should at least double the duration of data exclusivity to bring it closer to allowances awarded in the European Union, Japan and Canada. Congress is currently debating a rule allowing 12-year data exclusivity for biologic drugs. These drugs include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues and recombinant therapeutic proteins.

Currently, the researchers are continuing their investigations into the causes of pharmaceutical productivity decline through a recently formalized relationship that allows them access to IMS Health's databases. The relationship came through Georgia Tech's connection with former IMS board member and Georgia Tech alum John Imlay. The company's databases -- widely considered the gold standard in pharmaceutical and healthcare market intelligence -- cover the entire life cycle of drugs from how doctors and patients used them to how they fared in the marketplace.

In other research, Higgins and Graham are investigating the causes and responses of internal productivity declines experienced by the pharmaceutical industry and Graham is examining the importance of patenting to startup biotechnology firms.


Contact: Abby Vogel
Georgia Institute of Technology Research News

Related medicine news :

1. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
2. Spectranetics to Appeal Decision in Patent Litigation
3. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
4. Actavis Confirms its Patent Challenge of Kings Avinza(R)
5. PartsSource Awarded US Patent for PartsFinder(TM) Application
6. Barr Confirms Patent Challenge of UROXATRAL(R)
7. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
8. VNUS Medicals Patent Lawsuit Against Laser Competitors to Proceed to Trial
9. Aida Granted Additional Anti-Cancer Patent
10. China Medicines ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province
11. Wiley X Eyewear(R) Announces Successful Resolution of Patent Infringement Litigation Against PanOptx(R), Inc.
Post Your Comments:
Related Image:
Patent challenges reduce pharmaceutical innovation and productivity, researchers suggest
(Date:11/24/2015)... , ... November 24, 2015 , ... It takes only ... a business, it is critical that the first impression be positive and reflects business ... not likely to buy anything or want to return. They will also share their ...
(Date:11/24/2015)... ... 24, 2015 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Based in Jefferson City, Missouri, their core philosophy ... regardless of whether that client is a business, a family, or an individual. ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Serenity Point Rehabilitation, ... series of recent video interviews with some of the staff members at their recovery ... residential treatment facility, as well as some of the things that make their recovery ...
(Date:11/24/2015)... ... 2015 , ... Abington Hospital – Jefferson Health is pleased ... Surgery Facility for treating individuals living with morbid or extreme obesity. , Aetna ... its members to help them make informed decisions about their healthcare needs. In ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 iRhythm Technologies, Inc. , a ... today announced that it will participate in the 27th Annual Piper ... New York, NY . Kevin King , ... December 1, 2015 at 8:50am ET. --> ... . --> . --> iRhythm ...
(Date:11/24/2015)... Ontario , Nov. 24, 2015 Teledyne ... digital X-Ray image sensing technology, will introduce its CMOS ... Technical Exhibition , November 29 to December 3, at McCormick ... of dynamic detectors for diagnostic and interventional imaging will be ... Xineos family of advanced CMOS X-Ray detectors is ...
(Date:11/24/2015)... The uptake of recently approved and pipeline premium products for ... growth to 2021, says GBI Research . ... Type 1 Diabetes Mellitus (T1DM), will be a key driver of market ... --> The uptake of recently approved and pipeline premium products ... market growth to 2021, says GBI Research . ...
Breaking Medicine Technology: